Medical Specialties Hospital, Boulevard Milenio 130, San Carlos la Roncha, 37660, Leon, Guanajuato, Mexico.
Department of Genetics, National Institute of Rehabilitation, Avenue Mexico-Xochimilco 289, 14389, Mexico City, Mexico.
World J Pediatr. 2018 Jun;14(3):298-304. doi: 10.1007/s12519-018-0140-z. Epub 2018 Jun 6.
Giant axonal neuropathy (GAN) is a rare neurodegenerative disease transmitted in an autosomal recessive mode. This disorder presents motor and sensitive symptoms with an onset in early childhood. Progressive neurodegeneration makes the patients wheelchair dependent by the end of the second decade of life. Affected individuals do not survive beyond the third decade of life. Molecular analysis has identified mutations in the gene GAN in patients with this disorder. This gene produces a protein called gigaxonin which is presumably involved in protein degradation via the ubiquitin-proteasome system. However, the underlying molecular mechanism is not clearly understood yet.
Here we present the first patient from Mexico with clinical data suggesting GAN. Sequencing of the GAN gene was carried out. Changes in the nucleotide sequence were investigated for their possible impact on protein function and structure using the publicly available prediction tools PolyPhen-2 and PANTHER.
The patient is a compound heterozygous carrying two novel mutations in the GAN gene. The sequence analysis revealed two missense mutations in the Kelch repeats domain. In one allele, a C>T transition was found in exon 9 at the nucleotide position 55393 (g.55393C>T). In the other allele, a transversion G>T in exon 11 at the nucleotide position 67471 (g.67471G>T) was observed. Both of the bioinformatic tools predicted that these amino acid substitutions would have a negative impact on gigaxonin's function.
This work provides useful information for health professionals and expands the spectrum of disease-causing mutations in the GAN gene and it is the first documented case in Mexican population.
巨轴索神经病(GAN)是一种罕见的常染色体隐性遗传的神经退行性疾病。这种疾病表现为运动和感觉症状,在儿童早期发病。进行性神经退行性变使患者在 20 岁出头时依赖轮椅。受影响的个体无法存活到 30 岁以后。分子分析已在患有这种疾病的患者中发现了 GAN 基因的突变。该基因产生一种称为 gigaxonin 的蛋白质,据推测它参与了通过泛素-蛋白酶体系统的蛋白质降解。然而,其潜在的分子机制尚不清楚。
我们在这里介绍了来自墨西哥的首例具有 GAN 临床数据的患者。对 GAN 基因进行测序。使用公共可用的预测工具 PolyPhen-2 和 PANTHER 研究核苷酸序列的变化,以了解其对蛋白质功能和结构的可能影响。
该患者是携带 GAN 基因两个新突变的复合杂合子。序列分析显示 Kelch 重复结构域存在两个错义突变。在一个等位基因中,在核苷酸位置 55393(g.55393C>T)的外显子 9 中发现 C>T 转换。在另一个等位基因中,在核苷酸位置 67471(g.67471G>T)的外显子 11 中观察到 G>T 颠换。这两种生物信息学工具都预测这些氨基酸取代会对 gigaxonin 的功能产生负面影响。
这项工作为卫生专业人员提供了有用的信息,扩展了 GAN 基因致病突变的范围,这也是在墨西哥人群中记录的首例病例。